Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Fraser

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Journal of Critical Care|June 27, 2018
Feasibility of the electrolarynx for enabling communication in the chronically critically ill: The EECCHO studyLouise Rose, Laura Istanboulian, Orla M Smith, et al.
Journal of Critical Care|September 29, 2022
Co-designed and consensus based development of a quality improvement checklist of patient and family-centered actionable processes of care for adults with persistent critical illnessLouise Rose, Laura Istanboulian, Andre Carlos Kajdacsy-Balla Amaral, et al.
Psychopharmacology|December 25, 2010
Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatementJames R Shoblock, Natalie Welty, Leah Aluisio, et al.
Healthcare Quarterly (Toronto, Ont.)|November 27, 2020
Mobilizing a Whole Community: Policy and Strategy Implications of an Integrated Local System Response to a Global Health CrisisAnne Wojtak, Jason Altenberg, Carol Annett, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 21, 2018
Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedoniaAnindya Bhattacharya, Brian Lord, Jan-Sebastian Grigoleit, et al.
British Journal of Pharmacology|July 30, 2013
Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567Anindya Bhattacharya, Qi Wang, Hong Ao, et al.
British Journal of Pharmacology|May 14, 2025
Pharmacological characterisation of JNJ-78911118, a novel, centrally-penetrant, selective GluN2A antagonistBrian Lord, Sirak Simavorian, Ian Fraser, et al.
Psychopharmacology|November 19, 2010
JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in ratsRuggero Galici, Amir H Rezvani, Leah Aluisio, et al.
Cardiology in the Young|November 21, 2024
The long-term vascular and myocardial outcomes in selected Kawasaki disease patients with regression of giant coronary artery aneurysmsSamuel C Kung, Koichi Miyata, Gabrielle M Colvert, et al.
Psychopharmacology|December 3, 2009
In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptorJames R Shoblock, Natalie Welty, Diane Nepomuceno, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Journal of Critical Care|June 27, 2018
Feasibility of the electrolarynx for enabling communication in the chronically critically ill: The EECCHO studyLouise Rose, Laura Istanboulian, Orla M Smith, et al.
Journal of Critical Care|September 29, 2022
Co-designed and consensus based development of a quality improvement checklist of patient and family-centered actionable processes of care for adults with persistent critical illnessLouise Rose, Laura Istanboulian, Andre Carlos Kajdacsy-Balla Amaral, et al.
Psychopharmacology|December 25, 2010
Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatementJames R Shoblock, Natalie Welty, Leah Aluisio, et al.
Healthcare Quarterly (Toronto, Ont.)|November 27, 2020
Mobilizing a Whole Community: Policy and Strategy Implications of an Integrated Local System Response to a Global Health CrisisAnne Wojtak, Jason Altenberg, Carol Annett, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 21, 2018
Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedoniaAnindya Bhattacharya, Brian Lord, Jan-Sebastian Grigoleit, et al.
British Journal of Pharmacology|July 30, 2013
Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567Anindya Bhattacharya, Qi Wang, Hong Ao, et al.
British Journal of Pharmacology|May 14, 2025
Pharmacological characterisation of JNJ-78911118, a novel, centrally-penetrant, selective GluN2A antagonistBrian Lord, Sirak Simavorian, Ian Fraser, et al.
Psychopharmacology|November 19, 2010
JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in ratsRuggero Galici, Amir H Rezvani, Leah Aluisio, et al.
Cardiology in the Young|November 21, 2024
The long-term vascular and myocardial outcomes in selected Kawasaki disease patients with regression of giant coronary artery aneurysmsSamuel C Kung, Koichi Miyata, Gabrielle M Colvert, et al.
Psychopharmacology|December 3, 2009
In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptorJames R Shoblock, Natalie Welty, Diane Nepomuceno, et al.
Pageof 8